



Michael C Heinrich

Contact

Michael C Heinrich

Publications (5)

Schittenhelm M, Kampa-Schittenhelm K, Yee K, Heinrich M. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. *Cell Cycle* 2009; 8:2621-30.

Schittenhelm M, Bokemeyer C, Wong K, Corless C, Kanz L, Störkel S, Kurek R, Honecker F, Morich J, Harlow A, Oechsle K, Kollmannsberger C, Heinrich M. Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer. *Mol Cancer Ther* 2009; 8:481-9.

Fröhling S, Jiang J, Schittenhelm M, Lee B, Griffin J, Stone R, Heinrich M, Deininger M, Druker B, Golub T, Teckie S, Ebert B, Scholl C, Levine R, Loriaux M, Boggon T, Bernard O, Berger R, Döhner H, Döhner K, Gilliland D. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. *Cancer Cell* 2007; 12:501-13.

Schittenhelm M, Druker B, Deininger M, Bokemeyer C, Lee F, Griffith D, Corbin A, Schroeder A, Shiraga S, Heinrich M. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. *Cancer Res* 2006; 66:473-81.

Yee K, Schittenhelm M, O'Farrell A, Town A, McGreevey L, Bainbridge T, Cherrington J, Heinrich M. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. *Blood* 2004; 104:4202-9.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch